Corbus Pharmaceuticals Reports 2017 Second Quarter Financial Results

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) announced their financial results for the second quarter of 2017 and provided a business update.
As quoted in the press release:

The Company also provided an update to its corporate progress, clinical status and anticipated milestones for anabasum, its novel synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrosis.

“We have made significant progress on the corporate, operational and clinical fronts, enabling the Company to move forward with a strong balance sheet and plans to execute on multiple potentially impactful milestones coming up in the second half of this year,” stated Yuval Cohen, Ph.D., Chief Executive Officer of the Company.

Click here to read the full press release.

Source: www.marketwired.com